These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 1967976)

  • 1. Differential modulation of striatonigral dynorphin and enkephalin by dopamine receptor subtypes.
    Jiang HK; McGinty JF; Hong JS
    Brain Res; 1990 Jan; 507(1):57-64. PubMed ID: 1967976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of dopamine D-1 and D-2 receptor subtype agonists on nigrostriatal opioid dynorphin and enkephalin immunostaining in 6-hydroxydopamine lesioned rats.
    Jiang HK; Wang JY
    Chin J Physiol; 1991; 34(4):413-25. PubMed ID: 1687937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.
    Bronstein DM; Ye H; Pennypacker KR; Hudson PM; Hong JS
    Brain Res Mol Brain Res; 1994 May; 23(3):191-203. PubMed ID: 7914658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic modulation of striatal neuropeptides: differential effects of D1 and D2 receptor stimulation on somatostatin, neuropeptide Y, neurotensin, dynorphin and enkephalin.
    Engber TM; Boldry RC; Kuo S; Chase TN
    Brain Res; 1992 May; 581(2):261-8. PubMed ID: 1356580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.
    Gerfen CR; Engber TM; Mahan LC; Susel Z; Chase TN; Monsma FJ; Sibley DR
    Science; 1990 Dec; 250(4986):1429-32. PubMed ID: 2147780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nigral D1 and striatal D2 receptors mediate the behavioral effects of dopamine agonists.
    LaHoste GJ; Marshall JF
    Behav Brain Res; 1990 May; 38(3):233-42. PubMed ID: 1973041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation.
    Hu XT; Wachtel SR; Galloway MP; White FJ
    J Neurosci; 1990 Jul; 10(7):2318-29. PubMed ID: 1973947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential regulation of striatal preproenkephalin mRNA by D1 and D2 dopamine receptors.
    Pollack AE; Wooten GF
    Brain Res Mol Brain Res; 1992 Jan; 12(1-3):111-9. PubMed ID: 1312196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum.
    Li SJ; Jiang HK; Stachowiak MS; Hudson PM; Owyang V; Nanry K; Tilson HA; Hong JS
    Brain Res Mol Brain Res; 1990 Aug; 8(3):219-25. PubMed ID: 1977070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the substantia nigra in the expression of dopamine D1 receptor-mediated and D2 receptor-mediated behaviours.
    Fletcher GH; Starr MS
    Neuroscience; 1987 Dec; 23(3):1001-10. PubMed ID: 2963970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR; Hu XT; Galloway MP; White FJ
    Synapse; 1989; 4(4):327-46. PubMed ID: 2532422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prior D1 dopamine receptor stimulation is required to prime D2-mediated striatal Fos expression in 6-hydroxydopamine-lesioned rats.
    Pollack AE; Yates TM
    Neuroscience; 1999; 94(2):505-14. PubMed ID: 10579212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of chronic dopamine D1 and D2 receptor agonists on rotational behavior and dopamine receptor binding.
    Engber TM; Marin C; Susel Z; Chase TN
    Eur J Pharmacol; 1993 Jun; 236(3):385-93. PubMed ID: 8102970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.
    Sivam SP; Breese GR; Krause JE; Napier TC; Mueller RA; Hong JS
    J Neurochem; 1987 Nov; 49(5):1623-33. PubMed ID: 2889804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electrophysiological effects of SKF 38393 in rats with reserpine treatment and 6-hydroxydopamine-induced nigrostriatal lesions reveal two types of plasticity in D1 dopamine receptor modulation of basal ganglia output.
    Huang KX; Walters JR
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1434-43. PubMed ID: 7996456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
    Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
    Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK; Manzino L; Heikkila RE
    J Pharmacol Exp Ther; 1988 Oct; 247(1):180-5. PubMed ID: 2971797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.